EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication

Igor Andrade Santos, Victoria Riquena Grosche, Laiane Dos Santos Oliveira, Pedro Henrique de Souza Guarda, Gustavo Clauss Rodrigues, Rayany Cristina de Souza, Deborah Cristina Teixeira Alves, Andres Merits, Robinson Sabino-Silva, Dalan Bailey, Camilla Abbehausen, Mark Harris und 1 weitere

Journal of General Virology · 07.05.2026 · 107 (5)

DOI: 10.1099/jgv.0.002245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of General Virology, erschienen am 07.05.2026. Verfasst von Igor Andrade Santos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil. Hauptthemen laut MEDLINE: Antiviral Agents, Chalcones, Copper, SARS-CoV-2. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Medical Research Council, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chalcones, a naturally occurring class of molecules found in various plants, serve as both precursors and final products in the biosynthesis of flavonoids. Renowned for their diverse therapeutic actions, chalcones demonstrate anti-inflammatory, antitumoral, antimalarial and antiviral activities. The structure of chalcones allows chemical manipulation, making them attractive for metal coordination, such as with copper, an essential metal for living organisms. Here, we characterize the activity of CuL 2 phen and CuL 1 phen against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in which L1 and L2 are two forms of the chalcones 3-(4-(benzyloxy)phenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one and 3-(4-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one, respectively, and phen is phenanthroline. CuL 1 phen and CuL 2 phen anti-SARS-CoV-2 activity were studied in the viral replication cycle employing both the SARS-CoV-2-NeonGreen infectious clone and wild-type isolates. The SI of CuL 1 phen and CuL 2 phen was found to be 1.7 and 5.5, respectively, demonstrating that CuL 2 phen is a more promising compound. CuL 2 phen impaired SARS-CoV-2 entry, predicted by molecular docking calculations to disrupt the glycoprotein S and angiotensin-converting enzyme 2 (ACE2) binding, emphasized by the low EC 50 in pseudotyped virus entry assay. Further, CuL 2 phen was identified as SARS-CoV-2 post-entry inhibitor, probably due to its strong interaction with SARS-CoV-2 double stranded RNA. Altogether, the data suggest that CuL 2 phen acts by impairing SARS-CoV-2 entry by disrupting the viral envelope as well as interrupting RNA replication through specifically intercalating into the dsRNA. The obtained results give us mechanistic insights into the activity of this promising Cu(II) metallodrug candidate in SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsChalconesCopperSARS-CoV-2Virus ReplicationBetacoronavirusHumansAnimalsChlorocebus aethiopsSpike Glycoprotein, CoronavirusMolecular Docking SimulationVero Cells

Stichwörter der Autor:innen

Cu(II) complexesantiviralschalconescoronavirus disease 2019 (COVID-19)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Substanzen

Antiviral AgentsChalconesCopperSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil.
  • School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK.
  • Viral Glycoproteins Group, The Pirbright Institute, Pirbright, Woking, UK.
  • Institute of Biosciences, Humanities and Exact Sciences, São Paulo State University, São Paulo, Brazil.
  • Institute of Chemistry, University of Campinas, Campinas, Brazil.
  • Innovation Centre in Salivary Diagnostics and Nanobiotechnology, Laboratory of Nanobiotechnology - "Luiz Ricardo Goulart", Department of Physiology, Institute of Biomedical Sciences, Federal University of Uberlandia, Ub…

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Medical Research Council
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Wellcome Trust
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Brazilian Federal Agency for the Support and Evaluation of Graduate Education
  • Medical Research Foundation
  • Brazilian National Council for Research and Development

Zitieren

APA

Santos, I. A., Grosche, V. R., Oliveira, L. D. S., Guarda, P. H. S., Rodrigues, G. C., de Souza, R. C., Alves, D. C. T., Merits, A., Sabino-Silva, R., Bailey, D., Abbehausen, C., Harris, M., & Jardim, A. C. G. (2026). Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication. Journal of General Virology, 107(5). https://doi.org/10.1099/jgv.0.002245

Vancouver

Santos IA, Grosche VR, Oliveira LDS, Guarda PHS, Rodrigues GC, de Souza RC, et al. Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication. Journal of General Virology. 2026;107(5). doi:10.1099/jgv.0.002245

BibTeX
@article{Santos2026,
  author = {Santos, Igor Andrade and Grosche, Victoria Riquena and Oliveira, Laiane Dos Santos and Guarda, Pedro Henrique de Souza and Rodrigues, Gustavo Clauss and de Souza, Rayany Cristina and Alves, Deborah Cristina Teixeira and Merits, Andres and Sabino-Silva, Robinson and Bailey, Dalan and Abbehausen, Camilla and Harris, Mark and Jardim, Ana Carolina Gomes},
  title = {Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication},
  journal = {Journal of General Virology},
  year = {2026},
  volume = {107},
  number = {5},
  doi = {10.1099/jgv.0.002245}
}
Kostenlos starten →